Sangamo Partners With CHDI

4/5/11

Sangamo Biosciences (NASDAQ: SGMO), the Richmond, CA-based drug developer, said today it has formed a collaboration with the New York-based CHDI Foundation to develop a new treatment for Huntington’s disease. Sangamo will use its targeted zinc-finger protein technology to aim at a gene that causes Huntington’s. Financial terms of the partnership weren’t disclosed.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @

Next Post

Related Topics

Related Posts

Xconomy’s Most Popular

  1. Don’t Panic, But We’ve Passed Peak Apple. And Google. And Facebook.
  2. With Big Bucks Chasing Big Data, Will Consumers Get a Cut?
  3. Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian
  4. 11 Reasons Why Flickr, Not Facebook, Is the Place to Put Your Photos
  5. Digital Lumens, Finding Its Identity, Brings Cost & Energy Savings to Light

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.